Breast cancer treatment timeline
Breast cancer treatment can vary greatly from person to person. Learn more about the average timelines for diagnostics, testing, treatment, and recovery.
- Medical Review: Pallav K. Mehta, MD
The timeline for breast cancer treatment can vary greatly from person to person. This is because no two people and no two breast cancers are the same. Making informed decisions can be one of the most important and challenging parts of navigating breast cancer — and it’s normal to feel overwhelmed and to wonder how long cancer treatment will be a central part of your life.
Each person’s treatment timeline depends on their unique situation. Below, we’ll provide general estimates of how long different treatment phases can last. The lengths of time we share here are broad, and that’s because of how personalized breast cancer treatment has become. Your care team will have the most information about your treatments and needs. It’s OK to ask how long they believe each step may take.
Treatment variations
There are many breast cancer treatments approved by the FDA. Not every person diagnosed with breast cancer needs all of these treatments. The treatments you receive will depend on many factors, including features of the cancer and information about you and your needs.
Features of the cancer that can direct treatment plans include:
- The cancer stage: Breast cancer can be stage I, II, III, or IV. Staging is a way to measure the extent of cancer in the body and how serious the cancer is.
- The hormone receptor status of the cancer: Knowing whether certain hormones help the cancer grow can help determine treatment options.
- The HER2 status of the cancer: Cancers that overexpress a gene called HER2 can be treated with medicines that target HER2.
- The cancer grade: Cancer grade is how similar the cancer cells look to normal breast cells. Grade helps doctors understand how slowly or quickly the cancer cells are growing and dividing.
- Results from genomic tests and genetic tests:
- Genomic tests, also called tumor biomarker tests, performed on a piece of cancerous tissue, look at the genes in cancer cells to help predict how cancer will respond to certain treatments.
- Genetic tests, also called genetic testing for an inherited mutation, performed on a blood sample, check to see if you carry an inherited mutation, such as a BRCA1 or BRCA2 mutation, that raises your risk of breast cancer. Testing positive for a BRCA1 or BRCA2 mutation can affect treatment decisions.
Information about you that can direct treatment plans includes:
- Your health at the time of diagnosis: If you have other health conditions, your care team will consider how those conditions impact your body and what medicines you are already taking when they decide which cancer treatments you can get.
- Whether you’ve started menopause: Some cancer treatments are only approved for people who have already stopped having their period.
- Whether you want breast reconstruction: For example, if you need radiation therapy and you also choose to have a mastectomy with breast reconstruction, radiation may be given before reconstruction to avoid the effects of radiation on a reconstructed breast.
- Your health insurance: Navigating the health insurance industry can sometimes delay the start of certain treatments while you get required approvals.
- Where you live: While most approved breast cancer treatments are widely available in the U.S., if you live in a rural area you may need to travel further to get treatment. And if you’re considering treatment through a clinical trial, you may only be able to get the trial treatment in some areas.
How long you’re in treatment will depend on which treatments you need to effectively remove or manage the cancer.
- In early-stage breast cancer, the goal of treatment is to remove the cancer from your body and reduce the risk of breast cancer coming back. Early-stage breast cancer includes stages 0 to III. Typically, the higher the stage, the farther the cancer cells have traveled away from the breast.
- The goals for metastatic breast cancer are different. Metastatic breast cancer includes stage IV. While it’s not curable, it is treatable, and treatment is ongoing. The goal is to live as long as possible with the best possible quality of life. This means choosing treatments to control the cancer and to manage side effects, and changing those treatments as needed. You and your oncologist will work together to choose treatments that work best for you.
In general, a person diagnosed with early-stage breast cancer can be in active treatment for about one year. Active treatment includes medicines, surgeries, and therapies that work to remove the cancer from the body. It does not include long-term hormonal therapies given to help stop the cancer from coming back after treatment ends.
Below is a timeline that shows each step between finding a lump (yourself, or during a regular scan) and the end of active treatment. The lengths of time we share are for the average experience, and they may be different from your own.
Diagnosis & testing
Seeing your doctor about a lump to getting a scan of the area: 1 to 2 weeks. Typically, doctors will try to schedule mammograms to check on lumps as soon as possible. If the scheduler suggests an appointment 3 or more weeks after a doctor has checked the lump or seen a suspicious area on a first mammogram, it’s important to ask for an earlier appointment.
Confirming a lump or other suspicious area on a scan to having a biopsy: 1 to 2 weeks. It’s normal to wait up to 2 weeks for a biopsy appointment. Some cancer centers will be able to schedule you sooner. A biopsy is a procedure in which a doctor takes a sample of tissue from the lump so that it can be tested for cancer.
Waiting for biopsy results: 2 to 4 days. Some labs are busier than others, and biopsy results can take a few days. Biopsy samples are tested for breast cancer cells, and if cancer is found, the cells may also be immediately tested for information that tells your doctor what type of breast cancer you have. Some doctors choose to wait to call you with biopsy results until they have the information on type and stage.
Getting your pathology report: No more than 7 to 10 business days. Your pathology report contains information about what was found in the biopsy tissue. Once you have all of this information, you and your doctors can start making treatment decisions.
Active treatment
For people with stages I to III breast cancer, active treatment starts with either surgery or neoadjuvant (pre-surgery) treatment. Pre-surgery treatments like chemotherapy or hormonal therapy can help shrink the tumor to allow for a lumpectomy instead of mastectomy. Pre-surgery treatment also shows your doctors how well the cancer responds to the treatment given. Not everyone receives neoadjuvant treatment. If you do not need neoadjuvant treatment, the first step of active breast cancer treatment is surgery.
Biopsy followed by neoadjuvant treatment
Date of biopsy to the start of neoadjuvant (pre-surgery) treatment: 1 to 4 weeks. In some cases, people need chemotherapy or targeted therapy before surgery. After your biopsy, it can take 1 to 2 weeks to meet with a medical oncologist to discuss neoadjuvant treatment, and another 1 to 2 weeks after meeting them to start. It can be overwhelming to wait up to 4 weeks to start treatment once you know you have breast cancer. It’s OK to feel worried, scared, or like things are taking too long. But know that waiting a month does sometimes happen, and it is not harmful to you.
Length of neoadjuvant treatment: 3 to 6 months. If you have pre-surgery hormonal therapy, it can last 6 months or more.
End of neoadjuvant treatment to surgery: 3 to 6 weeks. The break between neoadjuvant treatment and the surgery date is often the result of working within your doctors’ schedules, needing insurance approvals, or the type of treatment you receive. If you have neoadjuvant chemotherapy, it will likely be 3 to 6 weeks after finishing the chemotherapy before you have surgery. If you are taking neoadjuvant hormonal therapy, you may be able to keep taking it without needing to stop for surgery and continue taking it after surgery. If your blood cell counts are low after or you’re experiencing treatment side effects, your care team may recommend waiting for these to resolve before having surgery.
Biopsy followed by lumpectomy
Date of biopsy to lumpectomy: 1 to 3 weeks. Lumpectomy is the removal of the tumor and a small area of tissue around it.
Recovery from lumpectomy: 1 week.
Biopsy followed by mastectomy
Date of biopsy to mastectomy: 2 to 6 weeks, depending on reconstruction. Mastectomy is the removal of the whole breast or both breasts. If you choose to have mastectomy alone, it can take 2 to 4 weeks to have the surgery after your biopsy. If you want to have reconstruction at the same time that you have the mastectomy, the surgery date depends on the breast surgeon’s and plastic surgeon’s schedules. It’s common to wait 3 to 6 weeks for an appointment that will work with both teams.
Recovery from mastectomy alone: up to 3 weeks.
Recovery from mastectomy with reconstruction: timing varies. How long it takes to recover from reconstructive surgery depends on the type of reconstruction you choose. With a simple implant reconstruction, it can take 4 weeks to recover. With more complex kinds of reconstruction, such as using your own tissue, recovery can take 6 to 8 weeks or longer. Learn more about breast reconstruction.
Length of post-surgery chemotherapy: 2 to 5 months.
Length of radiation therapy: 3 to 6.5 weeks (standard) or 5 days (brachytherapy). Most people who need radiation therapy will have between 3 and 6.5 weeks of daily treatment. Some will be offered a shorter-term radiation treatment called brachytherapy, or internal radiation.
Length of targeted therapy: 1 to 1.5 years.
Length of immunotherapy: 1 year, overlapping surgery and surgical recovery.
Maintenance therapy after active treatment ends. If you have hormone receptor-positive breast cancer and were diagnosed at stages 0 to III, you’ll likely be given several years of hormonal therapy after active treatment ends. This long-term treatment works to keep the cancer from coming back and lasts anywhere from 5 to 10 years. Two other medicines can be given alongside hormonal therapy if you meet certain criteria:
- 1 year of olaparib (Lynparza), a PARP inhibitor, if you carry a BRCA1 or BRCA2 mutation.
- 2 years of abemaciclib (Verzenio), a CDK 4/6 inhibitor, if you have ER-positive, HER2-negative breast cancer and are considered high risk.
Does the length of treatment change because of the stage of breast cancer?
For the most part, the breast cancer stage won’t change how long each type of treatment is given. Which treatments you need will be based on the information about the cancer cells in your pathology report.
There are three situations in which stage impacts which treatments you may get.
- Stage 0: Also called ductal carcinoma in situ (DCIS), this type of breast cancer is confined to the ducts of the breast. People with DCIS may only need surgery and radiation therapy for active treatment.
- Stage IIIC: Stage IIIC breast cancer is often also inflammatory breast cancer, which develops quickly and affects the skin of the breast. Inflammatory breast cancer is treated differently and more aggressively than other types of early-stage breast cancer.
- Stage IV: If the breast cancer is stage IV metastatic disease, you stay on each treatment as long as it works against the cancer and your body is handling the treatment well. If a treatment stops working or you have severe side effects, you and your care team will decide on a new treatment to try.
Treatment delays
Hearing you have breast cancer can be overwhelming, and if the diagnosis is early-stage breast cancer, you may hope for the year of treatment to go by as quickly as possible. It’s important to know that the time between treatment types can sometimes get delayed by cancer-related issues or outside factors. Some reasons treatment may be delayed include:
- Managing treatment side effects: If you experience severe side effects, it’s possible your doctor will recommend you take a treatment break to ease them and to give your body rest. This can lengthen how long it takes to complete a treatment type, or it might delay the start of your next treatment.
- Coordinating schedules: When you’re planning treatments that involve more than one medical team, such as mastectomy (surgical oncology) with reconstruction (plastic surgery), it can sometimes take more time to find a date that works for everyone involved.
- Recovering from surgery: The recovery times we listed above are average experiences. If your body takes longer to heal, or if you have a complication like an infection at the surgical site, you may need more time to recover before starting your next treatment.
- Getting insurance approvals: Some health insurance plans require pre-approval before they’ll agree to pay for some aspects of medical care. It can be complicated and can take some time to manage. Many cancer centers now have financial counselors on staff who can help you figure out what your personal health plan needs.
- Pregnancy: You can be diagnosed with breast cancer at any time — even during pregnancy. Research shows that chemotherapy is safe for a baby when given in the second or third trimester. Other treatments, such as radiation and hormonal therapy, can harm the baby. If you’re pregnant and in treatment for breast cancer, you and your care team will make decisions to keep you and the baby safe.
Frequently asked questions
Making treatment decisions can be complicated. To make it a little easier, we talked with medical oncologist Pallav K. Mehta, MD, of MD Anderson Cancer Center at Cooper about some of your most common stage and timing questions.
How soon should you have surgery after breast cancer diagnosis?
Breast cancer is usually not a medical emergency, though it can feel like an emotional emergency. You want to schedule surgery sooner for more aggressive subtypes, but waiting 2 to 3 weeks rarely causes harm. If your cancer center is scheduling you 6 or more weeks out, talk to them about moving it up.
At what stage of breast cancer is the breast removed?
The breast can be removed with mastectomy surgery at any stage. There are medical and personal reasons to remove the whole breast. Medically, removing the whole breast is recommended if:
- The tumor is too large compared to the size of the breast to be removed with lumpectomy. (In some cases, though, neoadjuvant treatment can shrink the tumor to allow for lumpectomy.)
- There are tumors in more than one part of the breast.
- A biopsy confirms cancer in at least one part of the breast, and a mammogram shows signs of potential cancer in several additional areas of the breast.
- You have inflammatory breast cancer.
- Your medical history shows you can’t have radiation therapy, which is usually recommended after lumpectomy.
- You carry an inherited gene mutation that raises your risk of breast cancer.
You may choose mastectomy even if lumpectomy is an option. Some people prefer to have mastectomy if they are at high risk of breast cancer because of an inherited genetic mutation or if they are worried about the cancer coming back.
At what stage of cancer is chemotherapy used?
Stage doesn’t matter as much as the biology of the cancer — how the cancer cells behave. Any stage of breast cancer might need chemotherapy. Stage III almost always needs chemotherapy.
How long can you go without breast cancer treatment?
There are times when waiting a few weeks will not cause harm, but be sure to discuss waiting for treatment with you care team to understand your individual situation.
How long does it take to treat breast cancer?
A year of active treatment, and for some people, 5 to 10 years of maintenance therapy. With stage IV metastatic breast cancer, treatment is ongoing.
How to cure cancer without surgery?
As of 2022, curing breast cancer requires surgery.
Why should I have chemo before surgery for breast cancer?
Pre-surgery chemotherapy is given for several reasons. First, it can provide information about chemosensitivity, or how well the cancer responds to that chemotherapy regimen. Second, it can make the cancer easier to remove with surgery. Third, it gives the patient more time to make surgical decisions without delaying the start of treatment. This can include time spent waiting for the results of genetic testing for an inherited mutation, because being high risk for breast cancer can impact your surgical decisions.
Chemotherapy before surgery is not recommended for every person with breast cancer; your treatment will depend on your individual diagnosis.
Recommended articles
- The next steps after a breast cancer diagnosis
- Understanding your pathology report
- Questions to ask an oncologist
- How cancer is staged
- Coping with a breast cancer diagnosis
- Goals of metastatic breast cancer treatment
- Treating metastatic breast cancer for life
Related blogs & news
- The Choice: When Is Chemotherapy the Right Treatment for Breast Cancer?
- What to expect from a virtual appointment
- Skin care and scarring after breast cancer surgery and radiation therapy
- Taking steps to preserve fertility: Lauren Higgins
- Recovering from breast cancer surgery
Related downloads
View more downloadsStay connected
Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.
- 3-dimensional radiation therapy
- 4-hydroxytamoxifen
- ablation
- abnormal
- Abraxane
- absolute risk
- AC regimen
- AC-T regimen
- AC-T-T regimen
- AC-Taxol regimen
- AC-TH regimen
- accelerated partial-breast irradiation
- action study
- acupoint
- acupressure
- acupuncture
- acupuncture needle
- acupuncture point
- acupuncture point injection
- acupuncturist
- acustimulation
- acute
- acute pain
- adenocarcinoma
- adenopathy
- adenosis
- adjunct agent
- adjunct therapy
- adjunctive therapy
- adjuvant therapy
- advance directive
- advanced practice nurse
- adverse effect
- aerobic exercise
- agent study
- aggravating factor
- aggressive
- AJCC staging system
- Alkeran
- alkylating agent
- Allegra
- allopathic medicine
- alopecia
- amifostine
- aminoglutethimide
- amitriptyline
- anabolic steroid
- analgesic
- anaplastic
- anastrozole
- ancillary test
- anemia
- anesthesia
- anesthesiologist
- angiogenesis
- angiogenesis inhibitor
- antagonist
- anthracycline
- anti-anxiety medicine
- anti-idiotype vaccine
- anti-inflammatory
- antibody-dependent cellular cytotoxicity
- antibody therapy
- anticachexia
- anticancer antibiotic
- anticancer therapy
- anticonvulsant
- antidepressant
- antiemetic
- antiestrogen
- antifolate
- antigen-presenting cell vaccine
- antihormone therapy
- antimetabolite
- antimitotic agent
- antineoplastic
- antitumor
- anxiety
- anxiolytic
- Anzemet
- APN
- apocrine gland
- apoptosis
- aprepitant
- areola
- Aromasin
- aromatase inhibitor
- aromatherapy
- arthralgia
- ascites
- aspirate
- aspiration
- assay
- asthenia
- asymptomatic
- atypia
- atypical ductal hyperplasia
- atypical hyperplasia
- atypical lobular hyperplasia
- avoidance
- axillary lymph node
- axillary lymph node dissection
- BAK gel
- balloon catheter radiation
- baseline
- behavior modification
- best practice
- BI-RADS
- Biafine cream
- bias
- bilateral
- bilateral breast cancer
- bilateral prophylactic mastectomy
- bilateral salpingo-oophorectomy
- biofeedback
- biologic
- biopsy
- biopsy specimen
- biotherapy
- bisphosphonate
- bisphosphonate-associated osteonecrosis
- blinded study
- blood-brain barrier
- blood-brain barrier disruption
- blood cell count
- blood chemistry study
- board certified oncology pharmacy specialist
- body image
- body mass index
- bolus dose
- bone density
- bone metastasis
- bone mineral density scan
- bone scan
- bone-seeking radioisotope
- brachytherapy
- brain metastasis
- BRCA1
- BRCA2
- BRCAPro
- breast carcinoma in situ
- breast-conserving surgery
- breast density
- breast duct
- breast duct endoscopy
- breast lobe
- breast lobule
- breast reconstruction
- breast self-exam
- Brief Pain Inventory
- cachexia
- CAF regimen
- calcification
- cancer vaccine
- candidiasis
- capecitabine
- carboplatin
- carcinogen
- carcinoma
- carcinoma in situ
- carcinomatous meningitis
- carcinosis
- carcinostatic
- cardiotoxicity
- caregiver
- carmustine
- case-control study
- case report
- case series
- CAT scan
- CBC
- cell
- cell-cycle regulation
- cell proliferation
- central nervous system
- central nervous system metastasis
- central nervous system prophylaxis
- central venous access catheter
- cetuximab
- cevimeline
- chaplain
- charged-particle radiation therapy
- chemoembolization
- chemoimmunotherapy
- chemoprevention
- chemoprevention study
- chemoprotective
- chemoradiation
- chemosensitivity
- chemosensitivity assay
- chemosensitizer
- chemotherapeutic agent
- chemotherapy
- chest wall
- chest X-ray
- Chinese meridian theory
- chronic
- chronic pain
- cisplatin
- Claus model
- clergy
- clinical
- clinical breast exam
- clinical practice guidelines
- clinical researcher
- clinical resistance
- clinical series
- clinical stage
- clinical staging
- clinical study
- clinical trial
- clinician
- clodronate
- CMF regimen
- cognition
- cognitive behavior therapy
- cognitive therapy
- cohort
- cohort study
- coinsurance
- combination chemotherapy
- comedo carcinoma
- comfort care
- Coming Out
- Community Advisory Board
- comorbidity
- compassionate use trial
- complementary and alternative medicine
- complementary medicine
- complete metastasectomy
- complete remission
- complete response
- complex decongestive therapy
- compliance
- complication
- compression garment
- computed tomography scan
- concomitant
- concurrent therapy
- condition
- consolidation therapy
- constitutional acupuncture
- continuum of care
- contract research organization
- contraindication
- contralateral
- contrast material
- control group
- controlled clinical trial
- controlled study
- conventional medicine
- conventional therapy
- copayments
- cope
- coping skills
- core biopsy
- core needle biopsy
- corticosteroid
- counseling
- COX inhibitor
- cryoablation
- cryopreservation
- cryosurgery
- CT scan
- cultural competency
- cumulative dose
- cumulative exposure
- cure
- cutaneous
- cutaneous breast cancer
- cyclophosphamide
- cyclosporine
- CYP2D6 inhibitor
- cystosarcoma phyllodes
- cytopenia
- cytotoxic
- cytotoxic chemotherapy
- Cytoxan
- Data and Safety Monitoring Board
- DCIS
- de novo
- debulking
- deductible
- definitive surgery
- definitive treatment
- dehydration
- denosumab
- depression
- diagnosis
- diagnostic mammogram
- diagnostic procedure
- diagnostic technique
- diagnostic trial
- diameter
- diarrhea
- diaziquone
- DIEP flap
- dietary counseling
- dietary supplement
- dietitian
- differentiation
- diffuse
- digital mammography
- diphenhydramine
- discharge
- disease progression
- disease-specific survival rate
- distant cancer
- distant metastasis
- Distant recurrence
- distress
- DNR order
- docetaxel
- dolasetron
- dose
- dose-dense chemotherapy
- dose-dependent
- dose-limiting
- dose-rate
- double-blinded
- doxorubicin
- drain
- dronabinol
- droperidol
- drug interaction
- drug resistance
- drug therapy
- drug tolerance
- duct
- ductal carcinoma
- ductal carcinoma in situ
- ductal lavage
- duloxetine
- durable power of attorney
- dysfunction
- dysgeusia
- dyspepsia
- dyspnea
- early menopause
- early-stage breast cancer
- edema
- EEG biofeedback
- efficacy
- Eklund displacement views
- electroacupuncture
- electron beam
- eligibility criteria
- Ellence
- emesis
- emetic
- endocrine
- endocrine therapy
- endpoint
- energy healing
- enteral nutrition
- epidemiology
- epirubicin
- ER+
- ER-
- ER
- ER-PR-HER2/neu-
- eribulin mesylate
- erythema
- estradiol
- estrogen
- estrogen blocker
- estrogen receptor
- estrogen receptor-negative
- estrogen receptor-positive
- estrogen receptor test
- estrogen replacement therapy
- etanidazole
- etidronate
- everolimus
- Evista
- excision
- excisional biopsy
- exemestane
- expanded access trial
- experimental
- extranodal
- false-negative test result
- false-positive test result
- familial cancer
- family medical history
- Faslodex
- fast-neutron beam radiation
- fatigue
- FDA
- febrile neutropenia
- FEC regimen
- Femara
- fertility
- fexofenadine
- fibroadenoma
- fibrocystic breast changes
- fiducial marker
- film mammography
- fine-needle aspiration biopsy
- first-degree relative
- first-line therapy
- five-year survival rate
- fluorouracil
- fluoxetine
- FNA biopsy
- focal
- Food and Drug Administration
- Fosamax
- fractionation
- fulvestrant
- functional magnetic resonance imaging
- gadolinium
- Gail model
- gallium scan
- gamma irradiation
- Gamma Knife therapy
- gamma ray
- Gelclair
- gemcitabine
- gene
- gene expression profile
- gene therapy
- general anesthesia
- generalized anxiety disorder
- generic
- genetic
- genetic counseling
- genetic marker
- genetic marker of susceptibility
- genetic predisposition
- genetic profile
- genetic susceptibility
- genetic testing
- genetic testing
- genetics
- genome
- genome-wide association study
- genomic profile
- genomic test
- genomics
- gland
- Good Clinical Practice
- goserelin
- grade
- grading
- granisetron
- gross description
- Halaven
- hazard ratio
- healing touch
- Health Insurance Portability and Accountability Act
- healthcare provider
- healthcare proxy
- healthy control
- helical computed tomography
- HER2/neu
- Herceptin
- hereditary
- hereditary mutation
- heteronormative
- high-dose chemotherapy
- high-dose radiation
- high-energy proton therapy
- high grade
- high-risk cancer
- HIPPA
- histologic examination
- histology
- historic cohort study
- historical control subject
- homeopathic medicine
- hormonal therapy
- hormone
- hormone receptor
- hormone receptor test
- hormone replacement therapy
- hormone responsive
- hormone therapy
- hospice
- hot flash
- human epidermal growth factor receptor 2
- human participant protection regulations
- hydroxydaunorubicin
- hyperalimentation
- hypercalcemia
- hyperfractionated radiation therapy
- hyperfractionation
- hyperplasia
- hypersensitivity
- hypofractionated radiation therapy
- hypofractionation
- hypoxia
- ibandronate
- ibuprofen
- idiopathic
- image-guided radiation therapy
- imaging
- imaging procedure
- immune adjuvant
- immune function
- immune response
- immune system
- immune system tolerance
- immunization
- immunoassay
- immunocompromised
- immunodeficiency
- immunohistochemistry
- immunology
- immunomodulation
- immunosuppression
- immunotherapy
- implant
- implant displacement views
- implant radiation therapy
- implantable pump
- in network
- in situ
- incidence
- incision
- incisional biopsy
- indication
- indolent
- induction therapy
- infection
- infertile
- infertility
- infiltrating breast cancer
- infiltrating ductal carcinoma
- inflammation
- inflammatory breast cancer
- informed consent
- infusion
- ingestion
- inherited
- iniparib
- injection
- inoperable
- insomnia
- Institutional Review Board
- intensification therapy
- intensity-modulated radiation therapy
- interfering thought
- internal mammary lymph nodes
- internal radiation therapy
- International Unit
- internist
- interstitial radiation therapy
- intervention
- intervention group
- intra-arterial
- intracarotid infusion
- intradermal
- intraductal breast papilloma
- intraductal carcinoma
- intrahepatic
- intrahepatic infusion
- intramuscular
- intramuscular injection
- intraoperative radiation therapy
- intraoperative ultrasound
- intratumoral
- intravasation
- intravenous
- intravenous infusion
- intravenous injection
- intrusive thought
- intrusive thoughts
- invasive breast cancer
- invasive cancer
- invasive procedure
- investigational
- investigator
- ionizing radiation
- ipsilateral
- IRB
- irradiated
- irradiation
- irreversible toxicity
- ixabepilone
- joint pain
- Karnofsky Performance Status
- laboratory test
- lapatinib
- laser
- laser surgery
- laser therapy
- lassitude
- late effects
- late-stage cancer
- latent
- laxative
- LEEP
- legal aid organization
- lesion
- lethargy
- letrozole
- leukopenia
- levels of evidence
- Lexapro
- libido
- lidocaine
- ligation
- linac
- linear accelerator
- lipoma
- lisofylline
- liver metastasis
- liver scan
- living will
- lobaplatin
- lobe
- lobectomy
- lobular carcinoma
- lobular carcinoma in situ
- lobule
- local anesthesia
- local cancer
- local therapy
- localization
- localized
- locally advanced cancer
- locally recurrent cancer
- lomustine
- loop electrosurgical excision procedure
- loop excision
- lorazepam
- low grade
- lubricant
- lumbar puncture
- lumpectomy
- lung metastasis
- luteinizing hormone-releasing hormone agonist
- lymph
- lymph gland
- lymph node
- lymph node dissection
- lymph node drainage
- lymph node mapping
- lymph vessel
- lymphadenectomy
- lymphadenopathy
- lymphangiogram
- lymphangiography
- lymphatic basin
- lymphatic fluid
- lymphatic mapping
- lymphatic system
- lymphatic vessel
- lymphedema
- lymphography
- lymphoscintigraphy
- Lyrica
- lytic lesion
- macrocalcification
- magnetic resonance imaging
- magnetic resonance perfusion imaging
- magnetic resonance spectroscopic imaging
- mainstream medicine
- maintenance therapy
- male breast cancer
- malignancy
- malignant
- malignant pleural effusion
- malnutrition
- mammary
- mammary dysplasia
- mammary gland
- mammogram
- mammography
- MammoSite
- Mammotome
- mantle field
- MAO inhibitor
- margin
- marker
- mass
- massage therapy
- mastectomy
- mastitis
- maternal
- maximum tolerated dose
- mean survival time
- measurable disease
- medial supraclavicular lymph node
- median
- median survival time
- Medicaid
- medical castration
- medical device
- medical nutrition therapy
- medical oncologist
- Medicare
- medicine
- medullary breast carcinoma
- mega-voltage linear accelerator
- megestrol
- melphalan
- meningeal metastasis
- menopause
- menorrhagia
- menstrual cycle
- menstrual period
- menstruation
- mental health
- mental health counselor
- meridian
- mesna
- meta-analysis
- metallic
- metastasectomy
- metastasis
- metastasize
- metastatic
- methotrexate
- metoclopramide
- metronomic therapy
- microcalcification
- micrometastasis
- microscopic
- milk duct
- mind/body exercise
- mindfulness relaxation
- Miraluma test
- mitigate
- modified radical mastectomy
- molecular marker
- molecular medicine
- molecular risk assessment
- molecularly targeted therapy
- monoamine oxidase inhibitor
- monoclonal antibody
- morbidity
- mortality
- MRI
- MRSI
- MTD
- mTOR
- mucositis
- multicenter study
- multicentric breast cancer
- multidisciplinary
- multidisciplinary opinion
- multidrug resistance
- multidrug resistance inhibition
- multifocal breast cancer
- music therapy
- mutation
- mutation carrier
- myalgia
- myelosuppression
- nanoparticle paclitaxel
- narcotic
- National Cancer Institute
- National Center for Complementary and Alternative Medicine
- National Institutes of Health
- natural history study
- naturopathy
- nausea
- NCCAM
- NCI
- NCI clinical trials cooperative group
- needle biopsy
- needle localization
- needle-localized biopsy
- negative axillary lymph node
- negative test result
- neoadjuvant therapy
- neoplasm
- nerve
- nerve block
- neurocognitive
- neurologic
- neuropathy
- neurotoxicity
- neurotoxin
- neutropenia
- NIH
- nipple
- nipple discharge
- nitrosourea
- NMRI
- node-negative
- node-positive
- nodule
- nonblinded
- nonconsecutive case series
- noninvasive
- nonmalignant
- nonmetastatic
- nonprescription
- nonrandomized clinical trial
- nonsteroidal anti-inflammatory drug
- nonsteroidal aromatase inhibitor
- nontoxic
- normal range
- normative
- NP
- NPO
- NSAID
- nuclear grade
- nuclear magnetic resonance imaging
- nuclear medicine scan
- nurse
- nurse practitioner
- nutrition
- nutrition therapy
- nutritional counseling
- nutritional status
- nutritional supplement
- nutritionist
- obese
- objective improvement
- objective response
- observation
- observational study
- obstruction
- off-label
- olaparib
- oncologist
- oncology
- oncology nurse
- oncology pharmacy specialist
- oncolysis
- ondansetron
- onset of action
- oophorectomy
- open biopsy
- open label study
- open resection
- operable
- opiate
- opioid
- opportunistic infection
- oral
- organ
- orthodox medicine
- osteolytic
- osteonecrosis of the jaw
- osteopenia
- osteoporosis
- OTC
- out of network
- outcome
- outpatient
- ovarian
- ovarian ablation
- ovarian cancer
- ovarian suppression
- ovary
- over-the-counter
- overall survival rate
- overdose
- overexpress
- overweight
- ovulation
- PA
- paclitaxel
- paclitaxel albumin-stabilized nanoparticle formulation
- paclitaxel-loaded polymeric micelle
- Paget disease of the nipple
- pain threshold
- palliation
- palliative care
- palliative therapy
- palmar-plantar erythrodysesthesia
- palonosetron hydrochloride
- palpable disease
- palpation
- palpitation
- pamidronate
- panic
- papillary tumor
- Paraplatin
- parenteral nutrition
- paroxetine hydrochloride
- PARP
- PARP inhibitor
- partial-breast irradiation
- partial mastectomy
- partial oophorectomy
- partial remission or partial response
- pastoral counselor
- paternal
- pathologic fracture
- pathological stage
- pathological staging
- pathologist
- pathology report
- patient advocate
- Paxil
- peau d'orange
- pedigree
- peer-review process
- peer-reviewed scientific journal
- perfusion magnetic resonance imaging
- perimenopausal
- periodic neutropenia
- perioperative
- peripheral neuropathy
- peripheral venous catheter
- personal health record
- personal medical history
- personalized medicine
- Pertuzumab
- PET scan
- pharmacist
- phase I/II trial
- phase I trial
- phase II/III trial
- phase II trial
- phase III trial
- phase IV trial
- phlebotomy
- photon beam radiation therapy
- phyllodes tumor
- physical examination
- physical therapist
- physical therapy
- physician
- physician assistant
- physiologic
- PI3 kinase inhibitor
- pilocarpine
- pilot study
- placebo
- placebo-controlled
- plastic surgeon
- plastic surgery
- population study
- positive axillary lymph node
- positive test result
- positron emission tomography scan
- post-traumatic stress disorder
- postmenopausal
- postoperative
- postremission therapy
- potentiation
- power of attorney
- PR
- PR+
- PR-
- practitioner
- preauthorization
- precancerous
- preclinical study
- predictive factor
- pregabalin
- premalignant
- premature menopause
- premenopausal
- premium
- prescription
- prevention
- preventive
- preventive mastectomy
- primary care
- primary care doctor
- primary endpoint
- primary therapy
- primary treatment
- primary tumor
- Principal investigator
- prochlorperazine
- progesterone
- progesterone receptor
- progesterone receptor-negative
- progesterone receptor-positive
- progesterone receptor test
- progestin
- prognosis
- prognostic factor
- progression
- progression-free survival
- progressive disease
- Prolia
- proliferative index
- promegapoietin
- prophylactic
- prophylactic mastectomy
- prophylactic oophorectomy
- prophylactic surgery
- prophylaxis
- prospective
- prospective cohort study
- prosthesis
- protective factor
- protein
- protein-bound paclitaxel
- protein expression
- protein expression profile
- protocol
- proton
- proton magnetic resonance spectroscopic imaging
- pruritus
- psychiatrist
- psychological
- psychologist
- psychosocial
- psychotherapy
- PTSD
- pump
- punch biopsy
- qi
- qigong
- quadrantectomy
- quality assurance
- quality of life
- radiation
- radiation brachytherapy
- radiation dermatitis
- radiation fibrosis
- radiation necrosis
- radiation nurse
- radiation oncologist
- radiation physicist
- radiation surgery
- radiation therapist
- radiation therapy
- radical lymph node dissection
- radical mastectomy
- radioactive
- radioactive drug
- radioactive seed
- radioisotope
- radiologic exam
- radiologist
- radiology
- radionuclide
- radionuclide scanning
- radiopharmaceutical
- radiosensitization
- radiosensitizer
- radiosurgery
- radiotherapy
- raloxifene
- raloxifene hydrochloride
- randomization
- randomized clinical trial
- receptor
- RECIST
- reconstructive surgeon
- reconstructive surgery
- recreational therapy
- recurrence
- recurrent cancer
- referral
- reflexology
- refractory
- refractory cancer
- regimen
- regional
- regional anesthesia
- regional cancer
- regional chemotherapy
- regional lymph node
- regional lymph node dissection
- registered dietician
- regression
- rehabilitation
- rehabilitation specialist
- relapse
- relative survival rate
- relaxation technique
- remission
- remission induction therapy
- remote brachytherapy
- research nurse
- research study
- resectable
- resected
- resection
- residual disease
- resistant cancer
- resorption
- respite care
- response rate
- retrospective cohort study
- retrospective study
- risk factor
- Rubex
- salpingo-oophorectomy